drugset / Trial / NCT04109690
CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.
NaSingle-groupOpen-labelTreatment
Summary
The proposed study is of a Liposomal formulation of cytarabine and daunorubicin (CPX-351) in patients treated for higher-risk myelodysplastic syndromes (MDS) experiencing hypomethylating agent failure.
Timeline
- Start
- 2019-12-30
- Primary completion
- 2021-07-27
- Completion
- 2021-07-27
Outcome
Outcome not reported
Stopped (Enrollment): “Failure to enroll”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 65 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 100 mg/m2 | — |
| Subject | Daunorubicin | Small molecule | 29 mg/m2 | — |
| Subject | Daunorubicin | Small molecule | 44 mg/m2 | — |